Physician profile
Peili Lin
NPI 1821147620
$1,393.13
in general payments reported to CMS, 2019-2025
13 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $149 · 2022: $259 · 2023: $138 · 2024: $368 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $147.11 | 2019 | |
| Horizon Therapeutics Plc | $138.22 | 2023 | Tepezza |
| Lkc Technologies, INC. | $133.99 | 2025 | |
| Sight Sciences, INC. | $133.70 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $125.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $125.00 | 2024 | |
| Bausch & Lomb Americas INC. | $124.68 | 2024 | Xiidra, Miebo |
| Dompe US, INC. | $118.06 | 2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $112.47 | 2020 | |
| Abbvie INC. | $100.54 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.72 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peili Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.